Apotex Eyes C$1B Toronto IPO, Canada's Largest Since 2021

Apotex Prepares for Major Toronto IPO

Canadian generic drug manufacturer Apotex Inc. is planning an initial public offering in Toronto during the first half of the year. According to reports, the deal could raise as much as C$1 billion, or $730 million, potentially marking it as Canada’s largest IPO since 2021.

Market and Company Overview

This move follows the 2023 acquisition of Apotex by SK Capital Partners, a life-sciences focused investment firm based in New York, in a transaction valued between C$3 billion and C$4 billion. The planned offering has significant financial backing, with RBC Capital Markets, Jefferies Financial Group, and TD Securities serving as advisers.

Potential Economic and Market Impact

The Apotex IPO is set to be a significant test for the Canadian capital markets. A successful launch could signal renewed investor appetite for large-scale offerings and potentially encourage other companies to go public, revitalizing a market that has seen limited activity in recent years.

Summary and Outlook

While the offering is planned for the near future, sources familiar with the matter state that no final decisions on the exact timing or size have been confirmed. The plans remain subject to change based on market conditions and final strategic assessments by the company and its advisers.

FAQ

Q: How much is Apotex seeking to raise in its IPO?
A: The company is targeting up to C$1 billion, which is equivalent to approximately $730 million USD.

Q: When is the Apotex IPO expected to happen?
A: The planned timeframe for the initial public offering is within the first half of the current year.

Source: Investing.com